Isoptin 80

Verapamil Hydrochloride, the active ingredient in Isoptin 80, is a calcium channel blocker presented as an 80 mg tablet for oral use. It is employed to lower high blood pressure, relieve chest pain from angina, and control certain rapid heart rhythms such as atrial fibrillation in adult patients.

GNH USA supplies Isoptin 80 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, ensuring product integrity throughout the supply chain.

Isoptin 80 (verapamil) is used to manage cardiovascular conditions that involve excessive calcium‑mediated contraction.

Hypertension: lowers systemic vascular resistance, helping to achieve target blood pressure in adults. Angina pectoris: reduces myocardial contractility and oxygen demand, providing relief from chest pain during exertion. Supraventricular tachyarrhythmias: slows atrioventricular node conduction, aiding rate control in atrial fibrillation and atrial flutter.

Verapamil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Dizziness or light‑headedness: transient drop in blood pressure. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Nausea: mild upset stomach. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate requiring medical attention. - Heart block: impairment of electrical conduction through the AV node. - Hypotension: significant drop in blood pressure causing fainting. - Hepatotoxicity: abnormal liver function tests or liver injury. - Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Isoptin 80, clinicians should consider several safety precautions to minimize risk.

- Cardiac function assessment: evaluate baseline heart rate and conduction abnormalities before initiating therapy. - Concomitant beta‑blocker use: avoid excessive bradycardia by monitoring combined effects. - Hepatic impairment: adjust use in patients with liver dysfunction due to altered metabolism. - Renal impairment: use caution in severe kidney disease as clearance may be reduced. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Verapamil interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase verapamil plasma levels. - Digoxin: concurrent use can raise digoxin concentrations and risk toxicity. - Beta‑blockers: combined effect can cause severe bradycardia or AV block.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): increased risk of myopathy. - Antihypertensive agents (e.g., ACE inhibitors, diuretics): may enhance hypotensive effect. - Anticonvulsants inducing CYP3A4 (e.g., carbamazepine, phenytoin): may reduce verapamil efficacy.